会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS
    • 作为P2Y12拮抗剂的杂环吡唑类羧酰胺
    • WO2009080226A3
    • 2009-08-27
    • PCT/EP2008010572
    • 2008-12-12
    • SANOFIS AVENTISNAZARE MARCZECH GERNOTJUST MELITTAWEISS TILOHESSLER GERHARDKOHLMANN MARKUS
    • NAZARE MARCZECH GERNOTJUST MELITTAWEISS TILOHESSLER GERHARDKOHLMANN MARKUS
    • C07D403/14A61K31/496A61P7/02
    • C07D403/14
    • The present invention relates to compounds of the formula (I), wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    • 本发明涉及式(I)化合物,其中R1; R2; Z者除外; 一个; B; D组; Q; 焦耳; V; G和M具有权利要求中所示的含义。 式I的化合物是有价值的药理活性化合物。 它们对血小板表现出强烈的抗凝集作用,因此表现出抗血栓形成的作用, 用于治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血小板ADP受体P2Y12的可逆拮抗剂,并且通常可用于其中存在血小板ADP受体P2Y12的不期望的活化或用于治疗或预防血小板ADP受体P2Y12的抑制的条件 。 本发明还涉及式(I)化合物的制备方法,其用途,特别是药物中的活性成分,以及包含它们的药物制剂。
    • 3. 发明申请
    • DÉRIVÉS DE Λ/-HÉTÉROARYL-CARBOXAMIDES TRICYCLIQUES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
    • 三茂酰胺酰胺衍生物,其制备方法及其治疗方法
    • WO2009050348A1
    • 2009-04-23
    • PCT/FR2008/001141
    • 2008-07-31
    • SANOFIS-AVENTISDUBOIS, LaurentEVANNO, YannickMALANDA, André
    • DUBOIS, LaurentEVANNO, YannickMALANDA, André
    • C07D471/04A61K31/437A61P1/04A61P3/00A61P13/00A61P15/00A61P17/00A61P11/00A61P25/00A61P29/00A61P31/12A61P31/22C07D471/14C07D233/02C07D211/56A61P27/14A61P1/00
    • C07D471/04
    • L'invention concerne les dérivés de Λ/-hétéroaryl-carboxamides tricycliques, de formule générale (I) dans laquelle A représente, avec la liaison Z2-Z3 du bicycle auquel il est fusionné, un groupe C 4 -C 7 -cycloalkyle, un hétéroaryle monocyclique ou un hétérocycle monocyclique de 4 à 7 chaînons comprenant de un à trois hétéroatomes choisi parmi O, S ou N, y compris les atomes Z 2 et Z 3 ; Z 1 , Z 5 , Z 6 , Z 7 et Z 8 représentent, indépendamment l'un de l'autre, un atome d'azote, un atome de carbone ou un groupe C-R 2 ; Z 2 , Z 3 , Z 4 et Z 9 représentent, indépendamment l'un de l'autre, un atome d'azote ou un atome de carbone et Z 1 , Z 9 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 et Z 9 forment ensemble un hétéroaryle bicyclique lié à l'atome d'azote de l'amide ou du thioamide de formule (I) par les positions Z 5 , Z 6 , Z 7 ou Z 8 quand ces positions correspondent à un atome de carbone, l'un au moins des Z 4 , Z 5 , Z 6 , Z 7 , Z 8 et Z 9 correspondant à un atome d'azote; W représente un atome d'oxygène ou de soufre; P représente un groupe indolyle, pyrrolo[2,3-c]pyridinyle, pyrrolo[2,3-6]pyridinyle, pyrrolo[3,2- /}]pyridinyle ou pyrrolo[3,2-c]pyridinyle, ce groupe étant substitué. Procédé de préparation et application en thérapeutique.
    • 本发明涉及具有式(I)的三环N-杂芳基 - 甲酰胺衍生物,其中:A代表与其结合的自行车的Z2-Z3键,C4-C7-环烷基,单环杂芳基或 具有4至7个成员的单环杂环,其包含1至3个选自O,S或N的杂原子,包括原子Z2和Z3; Z1,Z5,Z6,Z7和Z8彼此独立地表示氮原子,碳原子或C-R2基团; Z2,Z3,Z4和Z9彼此独立地表示氮原子或碳原子,Z 1,Z 9,Z 3,Z 4,Z 5,Z 6,Z 7,Z 8和Z 9一起形成与氮原子连接的双环杂芳基 当所述位置对应于碳原子,对应于氮原子的Z 4,Z 5,Z 6,Z 7,Z 8和Z 9中的至少一个时,具有式(I)的酰胺或硫代酰胺具有位置Z5,Z6,Z7或Z8; W表示氧或硫原子; 并且P代表吲哚基,吡咯并[2,3-c]吡啶基,吡咯并[2,3-b]吡啶基,吡咯并[3,2-b]吡啶基或吡咯并[3,2-c]吡啶基, 被替代 本发明还涉及其制备方法及其治疗用途。
    • 7. 发明申请
    • SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS
    • 取代的四氢萘制造方法相同,它们作为药物
    • WO2009021740A3
    • 2009-05-14
    • PCT/EP2008006700
    • 2008-08-14
    • SANOFIS AVENTISSCHWINK LOTHARSTENGELIN SIEGFRIEDGOSSEL MATTHIASHAACK TORSTENLENNIG PETRA
    • SCHWINK LOTHARSTENGELIN SIEGFRIEDGOSSEL MATTHIASHAACK TORSTENLENNIG PETRA
    • C07D307/12A61P3/00
    • C07D405/12A61K31/397A61K31/4025A61K31/4525A61K31/4709A61K31/496A61K31/5377A61K31/541A61K31/55A61K31/553A61K45/06C07D307/12
    • The invention relates to substituted tetrahydronaphthalenes of formula (I), the physiologically tolerated salts thereof, the use thereof, medicaments containing at least one substituted tetrahydronaphthalene according to the invention and the use of the substituted tetrahydronaphthalenes according to the invention and derivatives thereof as MCH antagonists, wherein in the case that X = O, C(R43)(R43'), B = (C1-C6)alkyI, (C1-C4)alkoxy-(C1-C4)alkyl, hydroxy-(C1-C6)alkyl, a 3- to 10-membered mono-, bi- or spirocyclic non-aromatic ring, which can contain 0 to 3 heteroatoms, selected from the group oxygen, nitrogen and sulfur, wherein the ring system can be additionally substituted with one or several of the following substituents: F, CF3, (C1-C6)alkyI, O-(C1-C8)alkyl, (C1-C4)alkoxy-(C1-C4)alkyI, hydroxy-(C1-C4)alkyl, oxo, CO(R64), hydroxy; wherein in the case that X = C(R43)(R43'), L3 = C(R62)(R63)O, and a 4- to 10-membered mono-, bi- or spirocyclic non-aromatic ring, which contains 1 to 3 heteroatoms, selected from the group oxygen, nitrogen and sulfur, wherein the ring system can be additionally substituted with one or several of the following substituents: F, CF3, (C1-C6)alkyl, (C1-C4)alkyl, (C1-C4)alkoxy-(C1-C4)alkyl, hydroxy-(C1-C4)alkyl, oxo, CO(R64), hydroxy.
    • 本发明涉及式(I),以及它们的生理学可接受的盐,其制备的取代的四氢萘,含有至少一种本发明的取代的四氢化萘和使用本发明的取代的四氢萘和它们作为MCH拮抗剂的衍生物的药物,和当X = O,C (R43)(R43“),B =(C1-C6)-AlkyI,(C1-C4)烷氧基 - (C1-C4)烷基,羟基(C1-C6)烷基,3-至10- 元单 - ,二环或螺环非芳香环,其可以包括选自氧,氮和硫,其中该环系可以另外被一个或多个下列取代基取代选择0至3个杂原子:F,CF 3, (C1-C6)-AlkyI,O-(C1-C8)烷基,(C1-C4)烷氧基 - (C1-C4)-alkyI,羟基(C1-C4) - 烷基,氧代,CO(R64) ,羟基; 其中,在X = C(R43)(R43“),L3 = C(R62)(R63)O,和4-至10-元单环,双环或含有1至3个杂原子的螺环非芳族环 包括选自氧,氮和硫的,其中该环系可以另外被一个或多个下列取代基取代选自:F,CF 3,(C1-C6)烷基,(C1-C4)烷基,(C 1 -C C4)烷氧基(C1-C4)烷基,羟基(C1-C4) - 烷基,氧代,CO(R64),羟基; 意思。
    • 8. 发明申请
    • DERIVATIVES OF 4-AMINO-QUINAZOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS
    • 4-氨基喹唑啉的衍生物,其制备方法及其在治疗中的应用
    • WO2007042669A2
    • 2007-04-19
    • PCT/FR2006002286
    • 2006-10-11
    • SANOFIS AVENTISAUGEREAU JEAN-MICHELCOURTEMANCHE GILLESDESPEYROUX PIERREGESLIN MICHELTHOMAS ANNE
    • AUGEREAU JEAN-MICHELCOURTEMANCHE GILLESDESPEYROUX PIERREGESLIN MICHELTHOMAS ANNE
    • C07D401/12A61K31/517A61P3/04C07D405/14
    • C07D401/12C07D405/14
    • The invention relates to derivatives of 4-amino-quinazoline, having general formula (I) wherein: A, B = C 1-4 -alkylene which is optionally substituted; L = a single bond, C 1-2 -alkylene, -CH=CH- or -C=C-; groups C 1-2 -alkylene and -CH=CH- which are optionally substituted, or L = cycloprop-1,2-diyl; R = H, C 1-5 -alkyl, C 1-3 -fluoroalkyl, C 3-6 -cycloalkyl, -C(O)C 1-3 -alkyl, C 1-3 -alkylene-C 3-6 -cycloalkyl, -CH 2 -C=CH, C 2-4 -alkylene-NR a R b , C 1-3 -alkylene-X-C 1-3 -alkyl, in which X = O, SO 2 ; R 1 = aryl or heteroaryl which are optionally substituted; R 2 and R 3 = H, C 1-3 -alkyl or C 1-3 -fluoroalkyl, or R 2 and R 3 together form a cycloprop-1,1-diyl; R 4 = H, C 1-5 -alkyl, C 1-3 - fluoroalkyl, C 1-5 -alkoxy, -SF 5 , C 1-3 -alkylene-X-C 1-3 -alkyl, in which X = O or SO 2 , C 1-5 -alkylene- NR a R b , an aryl or a heteroaryl which are optionally substituted; R 5 = H, halogen, C 1-5 -alkyl, C 1-3 -fluoroalkyl, C 1-5 -alkoxy, C 3-6 -cycloalkyl, C 1-3 -alkylene-C 3-6 -cycloalkyl, C 1-3 -alkylene-O-C 1-3 -alkyl, C 1-3 -alkylene-(OH), C 1-3 -alkylene-X-C 1-3 -alkyl, in which X = S, SO or SO 2 , or R 5 = -NR a R b , C 1-3 -alkylene-NR a R b , aryl, C 1-3 -alkylene-aryl, -O-aryl, C 1-3 -alkylene-O-aryl, C 1-3 -alkylene-O-C 1-3 -alkylene-aryl, heteroaryl or C 1-3 -alkylene-heteroaryl which are optionally substituted, or R 5 = heterocycle which is optionally substituted by C 1-3 -alkyl, -C(O)C 1-3 -alkyl, -C(O)C 1-3 -fluoroalkyl, C 1-3 -alkylene-C 3-6 -cycloalkyl, C 1-3 -alkylene-aryl, C 1-3 -alkylene-heteroaryl which are optionally substituted; R 7 = H, halogen, C 1-5 -alkyl, C 1-13 -fluoroalkyl, C 1-5 -alkoxy, -COOH, -C(O)O-C 1-3 -alkyl, C 1-3 -fluoroalkoxy, C 1-3 -alkylene-(OH), -NO 2 , -CN, -X-C 1-3 -alkyl, in which X represents S, SO or SO 2 , or R 7 = -NR a R b , C 1-3 -alkylene-NR a R b , -C(O)-NR a R b , -C(O)-C 1-3 -alkyl, aryl, -O-aryl or heteroaryl which are optionally substituted; in the form of a base, an acid addition salt, a hydrate or a solvate. The invention also relates to the method of preparing said derivatives and to the use of same in therapeutics.
    • 本发明涉及具有通式(I)的4-氨基 - 喹唑啉的衍生物,其中:A,B =任选被取代的C 1-4亚烷基; L =单键,C 1-2亚烷基,-CH = CH-或-C = C-; 基团C 1-2-亚烷基和-CH = CH-,其任选被取代,或者L =环丙-1,2-二基; R = H,C 1-5烷基,C 1-3烷基,C 3-6环烷基,-C(O) )C 1-3烷基,C 1-3亚烷基-C 3-6环烷基,-CH 2, C≡CH,C≡2-4亚烷基-NR SUB a R b SUB 1-3, 其中X = O,SO 2 ;其中X = R 1 =任选被取代的芳基或杂芳基; R 2和R 3 = H,C 1-3 1-3烷基或C 1-3 1-3氟代烷基, 或R 2和R 3一起形成环丙-1,1-二基; R 4 = H,C 1-5烷基,C 1-3氟代烷基,C 1-5 1-5 烷氧基,-SF 5,C 1-3亚烷基-XC 1-3烷基,其中X = O或SO 亚烷基-NR a R b,芳基或杂芳基,其任选地被一个或多个 取代; R 5 = H,卤素,C 1-5烷基,C 1-3卤代烷基,C 1-5卤代烷基, C 1-6烷氧基,C 3-6环烷基,C 1-3亚烷基-C 3-6环烷基,C 1-3烷氧基, C 1-3亚烷基-OC 1-3亚烷基,C 1-3亚烷基 - (OH),C 1-3亚烷基 - 其中X = S,SO或SO 2,或R 5,其中R 1,R 2,R 3和R 4独立地选自氢,C 1 -C 4烷基,C 1 -C 4烷基, = -NR a R b,b C 1-3亚烷基-NR a R b b, 芳基,C 1-3亚烷基 - 芳基,-O-芳基,C 1-3亚烷基-O-芳基,C 1 -C 3亚烷基 - -3亚烷基-OC 1-3亚烷基 - 芳基,杂芳基或C 1-3亚烷基 - 杂芳基,其任选地被取代, R 5任选地被C 1-3烷基,-C(O)C 1-3烷基,-C(O)C 1-3烷基, O)C 1-3亚烷基,C 1-3亚烷基-C 3-6环烷基,C 1 -C 4亚烷基, 3亚烷基 - 芳基,C 1 -C 3 - 亚烷基 - 杂芳基,其任选地被取代; R 5 = H,卤素,C 1-5烷基,C 1-3卤代烷基,C 1-5卤代烷基, 烷氧基,-COOH,-C(O)OC 1-3烷基,C 1-3氟代烷氧基,C 1-3烷氧基, (OH), - NO 2,-CN,-XC 1-3烷基,其中X代表S,SO或SO 2 或R 7 = - NR R b ,C 1-3 - (O)-NR a R b,-C(O)NR b R c,-C(O)NR b R c, )-C 1-3烷基,芳基,-O-芳基或杂芳基,其任选被取代; 以碱的形式,酸加成盐,水合物或溶剂化物。 本发明还涉及制备所述衍生物的方法以及其在治疗中的用途。